Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2021

01-07-2021 | Nausea | Review Article

Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting

Authors: Zhaosheng Jin, Neil Daksla, Tong J. Gan

Published in: Drugs | Issue 10/2021

Login to get access

Abstract

Postoperative nausea and vomiting (PONV) are the second most frequent adverse events after surgery second only to postoperative pain. Despite the advances in antiemetics and implementation of multimodal prophylactic interventions, the clinical management of PONV remains problematic. Neurokinin-1 (NK-1) receptor is a tachykinin receptor found throughout the central and peripheral nervous systems, with a particular affinity towards substance P. NK-1 receptors interact with several parts of the neuronal pathway for nausea and vomiting. This includes the chemoreceptor trigger zone, the gastrointestinal tract, and dorsal motor nucleus of the vagus. NK-1 antagonists are thought to prevent nausea and vomiting by downregulating the emetogenic signals at those points. As more head-to-head trials are conducted between the various anti-emetics, there is emerging evidence that NK-1 antagonists may be more effective in preventing PONV than several other antiemetics currently in use. In this review, we will discuss the pharmacology of NK-1 antagonists, their efficacy in clinical practice, and how they could fit into the framework of PONV management.
Literature
1.
Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131(2):411–48.PubMedCrossRef
2.
Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85–113.PubMedCrossRef
3.
Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999;91(3):693–700.PubMedCrossRef
4.
Ryu JH, Sohn IS, Do SH. Controlled hypotension for middle ear surgery: a comparison between remifentanil and magnesium sulphate. Br J Anaesth. 2009;103(4):490–5.PubMedCrossRef
5.
Vari A, Gazzanelli S, Cavallaro G, De Toma G, Tarquini S, Guerra C, et al. Post-operative nausea and vomiting (PONV) after thyroid surgery: a prospective, randomized study comparing totally intravenous versus inhalational anesthetics. Am Surg. 2010;76(3):325–8.PubMedCrossRef
6.
Koivuranta M, Laara E, Snare L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52(5):443–9.PubMedCrossRef
7.
Parra-Sanchez I, Abdallah R, You J, Fu AZ, Grady M, Cummings K 3rd, et al. A time-motion economic analysis of postoperative nausea and vomiting in ambulatory surgery. Can J Anaesth. 2012;59(4):366–75.PubMedCrossRef
8.
Berger ER, Huffman KM, Fraker T, Petrick AT, Brethauer SA, Hall BL, et al. Prevalence and risk factors for bariatric surgery readmissions: findings from 130,007 admissions in the metabolic and bariatric surgery accreditation and quality improvement program. Ann Surg. 2018;267(1):122–31.PubMedCrossRef
9.
Pierre S, Whelan R. Nausea and vomiting after surgery. BJA Educ. 2012;13(1):28–32.
10.
Weibel S, Rücker G, Eberhart LH, Pace NL, Hartl HM, Jordan OL, et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Cochrane Database Syst Rev. 2020;10:Cd012859.PubMed
11.
Babic T, Browning KN. The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur J Pharmacol. 2014;5(722):38–47.CrossRef
12.
Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol. 1999;375(1–3):51–60.PubMedCrossRef
13.
Carpenter DO, Briggs DB, Strominger N. Behavioral and electrophysiological studies of peptide-induced emesis in dogs. Fed Proc. 1984;43(15):2952–4.PubMed
14.
Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res. 1984;11(3):277–81.PubMedCrossRef
15.
Knox AP, Strominger NL, Battles AH, Carpenter DO. Behavioral studies of emetic sensitivity in the ferret. Brain Res Bull. 1993;31(5):477–84.PubMedCrossRef
16.
Carpenter DO, Briggs DB, Strominger N. Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol. 1983;3(2):113–26.PubMedCrossRef
17.
Qian QH, Yue W, Chen WH, Yang ZH, Liu ZT, Wang YX. Effect of gingerol on substance P and NK1 receptor expression in a vomiting model of mink. Chin Med J. 2010;123(4):478–84.PubMed
18.
Ray AP, Chebolu S, Darmani NA. Receptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva). Pharmacol Biochem Behav. 2009;94(1):211–8.PubMedPubMedCentralCrossRef
19.
Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 1996;35(8):1121–9.PubMedCrossRef
20.
Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol. 1995;115(1):84–94.PubMedPubMedCentralCrossRef
21.
Dixon MK, Nathan NA, Hornby PJ. Immunocytochemical distribution of neurokinin 1 receptor in rat dorsal vagal complex. Peptides. 1998;19(5):913–23.PubMedCrossRef
22.
Sun X, Xu L, Guo F, Luo W, Gao S, Luan X. Neurokinin-1 receptor blocker CP-99 994 improved emesis induced by cisplatin via regulating the activity of gastric distention responsive neurons in the dorsal motor nucleus of vagus and enhancing gastric motility in rats. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2017;29(10):1–11.
23.
Lewis MW, Travagli RA. Effects of substance P on identified neurons of the rat dorsal motor nucleus of the vagus. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G164–72.PubMedCrossRef
24.
Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides. 1998;32(1):1–49.PubMedCrossRef
25.
Li C, Micci MA, Murthy KS, Pasricha PJ. Substance P is essential for maintaining gut muscle contractility: a novel role for coneurotransmission revealed by botulinum toxin. Am J Physiol Gastrointest Liver Physiol. 2014;306(10):G839–48.PubMedPubMedCentralCrossRef
26.
Yates BJ, Catanzaro MF, Miller DJ, McCall AA. Integration of vestibular and emetic gastrointestinal signals that produce nausea and vomiting: potential contributions to motion sickness. Exp Brain Res. 2014;232(8):2455–69.PubMedPubMedCentralCrossRef
27.
Diemunsch P, Gan TJ, Philip BK, Girao MJ, Eberhart L, Irwin MG, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007;99(2):202–11.PubMedCrossRef
28.
Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007;104(5):1082–9.PubMedCrossRef
29.
Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006;46(3):291–300.PubMedCrossRef
30.
Ibrahim MA, Preuss CV. Antiemetic neurokinin-1 receptor blockers. Treasure Island: StatPearls Publishing LLC; 2020.
31.
Singh PM, Borle A, Rewari V, Makkar JK, Trikha A, Sinha AC, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016;92(1084):87–98.PubMedCrossRef
32.
Moon HY, Baek CW, Choi GJ, Shin HY, Kang H, Jung YH, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol. 2014;14:68.PubMedPubMedCentralCrossRef
33.
Liu M, Zhang H, Du BX, Xu FY, Zou Z, Sui B, et al. Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(19):e762.CrossRef
34.
Ham SY, Shim YH, Kim EH, Son MJ, Park WS, Lee JS. Aprepitant for antiemesis after laparoscopic gynaecological surgery: a randomised controlled trial. Eur J Anaesthesiol. 2016;33(2):90–5.PubMedCrossRef
35.
Lim CS, Ko YK, Kim YH, Park SI, Kim JK, Kim MJ, et al. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting. Korean J Anesthesiol. 2013;64(3):212–7.PubMedPubMedCentralCrossRef
36.
Vallejo MC, Phelps AL, Ibinson JW, Barnes LR, Milord PJ, Romeo RC, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg. 2012;129(2):519–26.PubMedCrossRef
37.
Sinha AC, Singh PM, Williams NW, Ochroch EA, Goudra BG. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014;24(2):225–31.PubMedCrossRef
38.
Lee SJ, Lee SM, Kim SI, Ok SY, Kim SH, Park SY, et al. The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone. Korean J Anesthesiol. 2012;63(3):221–6.PubMedPubMedCentralCrossRef
39.
Kawano H, Matsumoto T, Hamaguchi E, Manabe S, Nakagawa M, Yamada A, et al. Antiemetic efficacy of combined aprepitant and dexamethasone in patients at high-risk of postoperative nausea and vomiting from epidural fentanyl analgesia. Minerva Anestesiol. 2015;81(4):362–8.PubMed
40.
Yoo JH, Kim SI, Chung JW, Jun MR, Han YM, Kim YJ. Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. Korean J Anesthesiol. 2018;71(6):440–6.PubMedPubMedCentralCrossRef
41.
de Morais LC, Sousa AM, Flora GF, Grigio TR, Guimarães GMN, Ashmawi HA. Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial. Acta Anaesthesiol Scand. 2018;62(4):483–92.PubMedCrossRef
42.
Spaniolas K, Nie L, Moller D, Tatarian T, Hesketh A, Yang J, et al. A comprehensive approach for the prevention of nausea and vomiting following sleeve gastrectomy: a randomized controlled trial. Obes Surg. 2020;30(11):4250–7.PubMedCrossRef
43.
Grigio TR, Sousa AM, Magalhães GGN, Ashmawi HA, Vieira JE. Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial. Clinics (Sao Paulo, Brazil). 2020;75:e1688.CrossRef
44.
Noguchi T, Umezaki Y, Takano R, Fujimoto T, Domon Y, Kubota K, et al. A novel [5.2.1]bicyclic amine is a potent analgesic without µ opioid activity. Bioorg Med Chem Lett. 2021;36:127790.PubMedCrossRef
45.
Liu Y, Hu Q, Yang J. Oliceridine for the management of acute postoperative pain. Ann Pharmacother. 2021;11:1060028020987679.
46.
Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008;8(11):1733–42.PubMedCrossRef
47.
48.
Kakuta N, Kume K, Hamaguchi E, Tsutsumi R, Mita N, Tanaka K, et al. The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study. J Anesth. 2015;29(6):836–41.PubMedCrossRef
49.
Murakami C, Kakuta N, Kume K, Sakai Y, Kasai A, Oyama T, et al. A comparison of fosaprepitant and ondansetron for preventing postoperative nausea and vomiting in moderate to high risk patients: a retrospective database analysis. Biomed Res Int. 2017;2017:5703528.PubMedPubMedCentralCrossRef
50.
Tsutsumi YM, Kakuta N, Soga T, Kume K, Hamaguchi E, Tsutsumi R, et al. The effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study. BioMed Res Int. 2014;2014:307025.PubMedPubMedCentralCrossRef
51.
Soga T, Kume K, Kakuta N, Hamaguchi E, Tsutsumi R, Kawanishi R, et al. Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study. J Anesth. 2015;29(5):696–701.PubMedCrossRef
52.
Atsuta J, Inoue S, Tanaka Y, Abe K, Nakase H, Kawaguchi M. Fosaprepitant versus droperidol for prevention of PONV in craniotomy: a randomized double-blind study. J Anesth. 2017;31(1):82–8.PubMedCrossRef
53.
Ottoboni T, Keller MR, Cravets M, Clendeninn N, Quart B. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a phase I, open-label, randomized, two-way crossover evaluation. Drug Des Dev Ther. 2018;12:429–35.CrossRef
54.
55.
Ottoboni T, Lauw M, Keller MR, Cravets M, Manhard K, Clendeninn N, et al. HTX-019 via 2-min injection or 30-min infusion in healthy subjects. Future Oncol (Lond, Engl). 2019;15(8):865–74.CrossRef
56.
Navari RM. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020;19(2):205–10.PubMedCrossRef
57.
Navari RM, Mosier MC. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. Onco Targets Ther. 2019;12:3277–84.PubMedPubMedCentralCrossRef
58.
Fakira AK, Devi LA, Kennedy PJ. Novel application for G protein-biased Mu opioid receptor agonists in opioid relapse prevention. Biol Psychiatry. 2020;88(12):896–7.PubMedCrossRefPubMedCentral
59.
60.
Ahmed H, Hammad AM, Abushouk AI, Zidan M, Salem M, Negida A, et al. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting. Curr Probl Cancer. 2018;42(2):241–55.PubMedCrossRef
61.
Gan T, Gu J, Singla N, Chung F, Pearman M, Bergese S, et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg. 2011;112(4):804–12.PubMedCrossRef
62.
Pellegatti M, Bordini E, Fizzotti P, Roberts A, Johnson B. Disposition and metabolism of radiolabeled casopitant in humans. Drug Metab Dispos Biol Fate Chem. 2009;37(8):1635–45.PubMedCrossRef
63.
Singla N, Singla S, Chung F, Kutsogiannis D, Blackburn L, Lane S, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology. 2010;113(1):74–82.PubMedCrossRef
64.
Altorjay A, Melson T, Chinachoit T, Kett A, Aqua K, Levin J, et al. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg. 2011;146(2):201–6.PubMedCrossRef
65.
Brigandi R, Russ S, Petit C, Johnson B, Croy S, Hodsman P, et al. Intravenous pharmacokinetics, local tolerability, and hemolysis of an SBE7-β-cyclodextrin formulation of the neurokinin-1 receptor antagonist vestipitant. Clin Pharmacol Drug Dev. 2015;4(2):130–6.PubMedCrossRef
66.
Kranke P, Thompson J, Dalby P, Eberhart L, Novikova E, Johnson B, et al. Comparison of vestipitant with ondansetron for the treatment of breakthrough postoperative nausea and vomiting after failed prophylaxis with ondansetron. Br J Anaesth. 2015;114(3):423–9.PubMedCrossRef
67.
Diemunsch P, Schoeffler P, Bryssine B, Cheli-Muller L, Lees J, McQuade B, et al. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth. 1999;82(2):274–6.PubMedCrossRef
68.
Gesztesi Z, Scuderi P, White P, Wright W, Wender R, D’Angelo R, et al. Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology. 2000;93(4):931–7.PubMedCrossRef
69.
Lucot JB. Effects of naloxone on motion sickness in cats alone and with broad spectrum antiemetics. Auton Neurosci Basic Clin. 2017;202:97–101.CrossRef
70.
Ormel G, Romundstad L, Lambert-Jensen P, Stubhaug A. Dexamethasone has additive effect when combined with ondansetron and droperidol for treatment of established PONV. Acta Anaesthesiol Scand. 2011;55(10):1196–205.PubMedCrossRef
71.
Choi YS, Sohn HM, Do SH, Min KT, Woo JH, Baik HJ. Comparison of ramosetron and ondansetron for the treatment of established postoperative nausea and vomiting after laparoscopic surgery: a prospective, randomized, double-blinded multicenter trial. Ther Clin Risk Manag. 2018;14:601–6.PubMedPubMedCentralCrossRef
72.
Candiotti KA, Kranke P, Bergese SD, Melson TI, Motsch J, Siddiqui N, et al. Randomized, double-blind, placebo-controlled study of intravenous amisulpride as treatment of established postoperative nausea and vomiting in patients who have had no prior prophylaxis. Anesth Analg. 2019;128(6):1098–105.PubMedCrossRef
73.
Habib AS, Gan TJ. The effectiveness of rescue antiemetics after failure of prophylaxis with ondansetron or droperidol: a preliminary report. J Clin Anesth. 2005;17(1):62–5.PubMedCrossRef
74.
Chan MTV, Choi KC, Gin T, Chui PT, Short TG, Yuen PM, et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg. 2006;103(5):1155–62.PubMedCrossRef
75.
Fick D, Semla T, Steinman M, Beizer J, Brandt N, Dombrowski R, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.CrossRef
76.
Marbury TC, Jin B, Panebianco D, Murphy MG, Sun H, Evans JK, et al. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. Anesth Analg. 2009;109(2):418–25.PubMedCrossRef
77.
Myles PS, Williams DL, Hendrata M, Anderson H, Weeks AM. Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J Anaesth. 2000;84(1):6–10.PubMedCrossRef
Metadata
Title
Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting
Authors
Zhaosheng Jin
Neil Daksla
Tong J. Gan
Publication date
01-07-2021
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2021
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-021-01532-y

Other articles of this Issue 10/2021

Drugs 10/2021 Go to the issue

Adis Drug Evaluation

Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain

AdisInsight Report

Loncastuximab Tesirine: First Approval

Correction

Correction to: Lazertinib: First Approval

Leading Article

Current Status of Clinical Trials on Tau Immunotherapies

AdisInsight Report

Dostarlimab: First Approval

Review Article

Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents